Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
International Journal of Pharmaceutics|February 22, 2015
Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trialAndreas Wicki, Reto Ritschard, Uli Loesch, et al.Journal of Drug Targeting|July 24, 2015
Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacyAnnette Orleth, Christoph Mamot, Christoph Rochlitz, et al.Journal of Drug Targeting|June 17, 2006
EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cellsChristoph Mamot, Reto Ritschard, Willy Küng, et al.Journal of Drug Targeting|April 24, 2012
Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cellsChristoph Mamot, Reto Ritschard, Andreas Wicki, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2011
Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growthAndreas Wicki, Christoph Rochlitz, Annette Orleth, et al.The Lancet. Oncology|November 17, 2012
Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation studyChristoph Mamot, Reto Ritschard, Andreas Wicki, et al.Cancer Immunology Research|April 16, 2025
Targeting cancer-associated glycosylation for adoptive T cell therapy of solid tumorsAndreas Zingg, Reto Ritschard, Helen Thut, et al.Frontiers in Oncology|March 22, 2021
Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor ImmunityMarina Natoli, Petra Herzig, Elham Pishali Bejestani, et al.European Journal of Cancer (Oxford, England : 1990)|April 17, 2018
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)Andreas Wicki, Nicholas Brown, Alexandros Xyrafas, et al.Cancer Immunology Research|April 17, 2024
Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating LymphocytesDavid König, Michael T Sandholzer, Sarp Uzun, et al.Pageof 2